Minimizing the risk of recurrent or progressive invasive mold infections during stem cell transplantation or further intensive chemotherapy

Transplant Infectious Disease

Volumn 10, Issue 1, 2008, Pages 3-12

  Grigg, A ^a   Slavin, M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Invasive fungal infection; Secondary prophylaxis; Stem cell transplantation

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CASPOFUNGIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GRANULOCYTE COLONY STIMULATING FACTOR; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; PREDNISOLONE; PYRROLE DERIVATIVE; RAPAMYCIN; TACROLIMUS; VORICONAZOLE;

ACUTE LEUKEMIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; GRAFT VERSUS HOST REACTION; GRANULOCYTE TRANSFUSION; HUMAN; INCIDENCE; INTENSIVE CARE; LIVER DYSFUNCTION; LIVER TOXICITY; LUNG ASPERGILLOSIS; LUNG LESION; LUNG SURGERY; MORTALITY; MUCORMYCOSIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUTROPENIA; PATIENT MONITORING; PERIOPERATIVE PERIOD; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; REVIEW; RISK FACTOR; SUSTAINED RELEASE PREPARATION; THORACOSCOPY; TREATMENT DURATION;

ANTIFUNGAL AGENTS; CHEMOPREVENTION; HEMATOLOGIC NEOPLASMS; HUMANS; MYCOSES; STEM CELL TRANSPLANTATION;

EID: 38649094244     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2007.00259.x     Document Type: Review

References (80)

1. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998 26 : 781 805.
2. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002 34 : 7 14.
3. Offner F, Cordonnier C, Ljungman P, et al. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998 26 : 1098 1103.
4. Fukuda T, Boeckh M, Guthrie KA, et al. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant 2004 10 : 494 503.
5. Martino R, Parody R, Fukuda T, et al. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2006 108 : 2928 2936.
6. Vaidya SJ, Ortin M, Lopez-Duarte M, et al. Haemopoietic progenitor cell transplantation in patients with previous history of invasive fungal infection. Leuk Lymphoma 2005 46 : 1143 1150.
7. Viollier AF, Peterson DE, De Jongh CA, et al. Aspergillus sinusitis in cancer patients. Cancer 1986 58 : 366 371.
8. Sipsas NV, Kontoyiannis DP. Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with haematological malignancies. Clin Infect Dis 2006 42 : 1584 1590.
9. Avivi I, Oren I, Haddad N, Rowe JM, Dann EJ. Stem cell transplantation post invasive fungal infection is a feasible task. Am J Hematol 2004 75 : 6 11.
10. Martino R, Subira M, Rovira M, et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002 116 : 475 482.
11. Matt P, Bernet F, Habicht J, et al. Predicting outcome after lung resection for invasive pulmonary aspergillosis in patients with neutropenia. Chest 2004 125 : 1783 1787.
12. Gastinne T, Touzeau C, Givouroux S, et al. Lung resection for invasive pulmonary aspergillosis in neutropenic patients with hematologic malignancies: long term results in thirty two cases. Blood 2006 108 : 809a, abstract 2857.
13. Storek J, Dawson MA, Storer B, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001 97 : 3380 3389.
14. Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2006 23 : 5074 5087.
15. Thursky K, Byrnes G, Grigg AP, Szer J, Slavin M. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant 2004 34 : 115 121.
16. Shao C, Qu J, He L, et al. Transient overexpression of γ interferon promotes aspergillus clearance in invasive pulmonary aspergillosis. Clin Exp Immunol 2005 142 : 233 241.
17. Schulenburg A, Fischer M, Kalhs P, et al. Immune recovery after conventional and non-myeloablative allogeneic stem cell transplantation. Leuk Lymphoma 2005 46 : 1755 1760.
18. Hagen EA, Stern H, Porter D, et al. High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. Clin Infect Dis 2003 36 : 9 15.
19. Junghanss C, Marr KA, Carter RA, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 2002 8 : 512 520.
20. Frere P, Baron F, Bonnet C, et al. Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen. Bone Marrow Transplant 2006 37 : 411 418.
21. Cornely OA, Martino R, Maschmeyer G, et al. Efficacy of caspofungin as secondary antifungal prophylaxis for prevention of breakthrough fungal infection: data from a multinational case registry [Abstract M 957]. The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington. Washington, DC : American Society for Microbiology, 2005.
22. Stute N, Kratochwille A, Szbelina T, et al. Caspofungin is highly effective as secondary prophylaxis in allogeneic stem cell transplantation in patients with prior systemic or invasive fungal infections. Bone Marrow Transplant 2004 33 (Suppl 1) : 735.
23. Kruger WH, Russmann B, de Wit M, et al. Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B. Acta Haematol 2005 113 : 104 108.
24. Cordonnier C, Maury S, Pautas C, et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004 33 : 943 948.
25. Panwalkar AW, DeVetten MP, Bociek G, Freifeld AG. Strategy for managing patients with prior invasive aspergillosis through allogeneic transplant. Blood 2006 106 : 421 422b, abstract 5318.
26. Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be essential to avoid subtherapeutic levels. Blood 2006 108 : 179a abstract 594.
27. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006 45 : 649 663.
28. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004 39 : 584 586.
29. Trifilio S, Singhal S, Williams S, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Blood 2006 108 : 806 807a, abstract 2849.
30. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002 34 : 563 571.
31. Trifilio S, Khalid MK, Pennick G. Voriconazole therapeutic drug monitoring: relationship between drug levels and liver function tests. Blood 2006 108 : 836a, abstract 2950.
32. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004 103 : 1527 1533.
33. Winston DJ, Emmanouilides C, Bartoni K, Schiller GJ, Paquette R, Territo MC. Elimination of aspergillus infection in allogeneic stem cell transplant recipients with long-term itraconazole prophylaxis: prevention is better than treatment. Blood 2004 104 : 1581.
34. Grigg AP, Brown M, Roberts AW, Szer J, Slavin M. A pilot study of targetted itraconazole prophylaxis in patients with graft versus host disease at high risk of invasive mold infections following allogeneic stem cell transplantation. Bone Marrow Transplant 2004 34 : 447 453.
35. Nosari A, Oreste P, Cairoli R, et al. Invasive aspergillosis in haematological malignancies: clinical findings and management for intensive chemotherapy completion. Am J Hematol 2001 68 : 231 236.
36. Wingard JR. The changing face of invasive fungal infections in hematopoietic cell transplant recipients. Curr Opin Oncol 2005 17 : 89 92.
37. Ullman AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007 356 : 335 347.
38. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007 356 : 348 359.
39. Krishna G, Wexler D, Shah A, Martinho M, Patino H. The pharmacokinetics of oral posaconazole in recipients of allogeneic hematopoietic stem cell transplantation with graft versus host disease [Abstract A-221]. The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington. Washington, DC : American Society for Microbiology, 2005.
40. Leather HL, Correll TA, Meyer CL, Schmalfuss IM, Wingard JR. Treatment of zygomycosis with posaconazole in a patient with acute myeloid leukemia. Clin Adv Hematol Oncol 2005 3 : 773 778.
41. Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006 42 : 1726 1734.
42. Courtney R. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Pharmacol 2003 57 : 218 222.
43. Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004 103 : 1557 1559.
44. Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004 21 : 645 653.
45. Kuypers DR, Claes K, Evenepoel P, Vanrenterghem Y. Clinically relevant drug interaction between voriconazole and tacrolimus in a primary renal allograft recipient. Transplantation 2006 81 : 1750 1752.
46. Romero AJ, Le Pogamp P, Nilsson LG, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002 71 : 226 234.
47. Courtney RD, Statkevich P, Laughlin M, Lim J, Clement RP, Batra VK. Effect of posaconazole on the pharmacokinetics of cyclosporine [Abstract 27]. The 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago. Washington, DC : American Society for Microbiology, 2001.
48. Sansone A, Belle D, Statkevich, et al. Effect of posaconazole on the pharmacokinetics of tacrolimus in healthy volunteers [Abstract A-1603]. The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago. Washington, DC : American Society for Microbiology, 2003.
49. Capone D. Effects of itraconazole on tacrolimus blood concentrations in a renal transplant recipient. Ann Pharmacother 1999 33 : 1124 1125.
50. Marty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005 12 : 552 559.
51. Sanz-Rodriguez C, Lopez-Duarte M, Jurado M, et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant 2004 34 : 13 20.
52. van Burik JH, Ratanatharathorn V, Stephan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004 39 : 1407 1416.
53. Penack O, Schwartz S, Martus P, et al. Low dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 2006 17 : 1306 1312.
54. Quilitz RE, Arnold AD, Briones GR, et al. Practice guidelines for lipid-based amphotericin B in stem cell transplant recipients. Ann Pharmacother 2001 35 : 206.
55. Jansen J, Akard LP, Wack MF, et al. Delayed ABLC prophylaxis after allogeneic stem-cell transplantation. Mycoses 2006 49 : 397 404.
56. Mattiuzzi GN, Kantarjian H, Faderl S, et al. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer 2004 100 : 581 589.
57. Myint H, Bolam S, Kyi AA, Creasy T. Prevention of recurrence of fungal pneumonia with prophylactic low dose amphotericin lipid complex (Abelcet) following myelosuppressive chemotherapy. 23rd annual meeting of the EBMT, March 1997, abstract P657.
58. Wolff SN, Fay J, Stevens D, et al. Fluconazole vs low dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group. Bone Marrow Transplant 2000 25 : 853 859.
59. Pascual AA, Bolar S, Marchetti O. Documentation of low voriconazole blood levels followed by dose adjustment in patients with invasive fungal infections not responding to therapy [Abstract M-1304]. The 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. Washington, DC : American Society for Microbiology, 2006.
60. Clarke K, Szer J, Shalton M, Coghlan D, Grigg AP. Multiple granulocyte transfusions facilitating successful unrelated bone marrow transplantation in a patient with very severe aplastic anemia complicated by suspected fungal infection. Bone Marrow Transplant 1995 16 : 723 726.
61. Grigull L, Beilken A, Schmid H, et al. Secondary prophylaxis of invasive fungal infections with combination antifungal therapy and G-CSF mobilized granulocyte transfusions in three children with haematological malignancies. Support Care Cancer 2006 14 : 783 786.
62. Mousset S, Hermann S, Klein SA, et al. Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann Hematol 2005 84 : 734 741.
63. Peters C, Seidel MG, Northoff H, et al. Granulocyte transfusions for treatment or prophylaxis of severe infections in immunocompromised neutropenic patients-a randomized clinical trial. Blood 2006 108 : 831a, abstract 2934.
64. Dekker A, Bulley S, Beyene J, Dupuis LL, Doyle JJ, Sung L. Meta analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol 2006 24 : 5207 5215.
65. ®) administration after PBSC transplantation: results of a SFGM-TC randomised trial. Bone Marrow Transplant 2005 26 : 547 552.
66. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001 19 : 253 259.
67. Hot A, Monory C, Lourlergue P, et al. Positron emission scanning with 18-FDG for the diagnosis of invasive fungal infections (IF) [Abstract M-1307]. The 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. Washington, DC : American Society for Microbiology, 2006.
68. Maufouz T, Miceli MH, Saghafifar F, et al. 18 F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes. J Clin Oncol 2005 23 : 7857 7863.
69. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a non-invasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001 97 : 1604 1610.
70. Woods G, Miceli M, Grazziutti M, et al. Validation of serum aspergillus galactomannan index as a surrogate endpoint for outcome of invasive aspergillosis: clinical and research implications. Blood 2006 108 : 810a, abstract 2861.
71. Hebart H, Loffler J, Meisner C, et al. Early detection of aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis 2000 181 : 1713 1719.
72. Jordanides NE, Allan EK, McLintock LA, et al. A prospective study of real-time panfungal PCR for the early diagnosis of invasive fungal infection in haemato-oncology patients. Bone Marrow Transplant 2005 34 : 389 395.
73. Rovira M, Jimenez M, de la Bellacasa JP, et al. Detectin of aspergillus galactomannan by enzyme immunoabsorbent assay in recipients of allogeneic hematopoietic stem cell transplantation: a prospective study. Transplantation 2004 77 : 1260 1264.
74. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2004 40 : 1762 1769.
75. Buchheidt D, Baust C, Skladny H, et al. Clinical evaluation of a polymerase chain reaction assay to detect aspergillus species in bronchoalveolar lavage samples of neutropenic patients. Br J Haematol 2002 116 : 803 811.
76. Peggs KS. Immune reconstitution following stem cell transplantation. Leuk Lymphoma 2004 45 : 1093 1101.
77. Rutella S, Pierelli L, Sico S, Rumi C, Leone G. Transplantation of autologous peripheral blood progenitor cells: impact of CD34- cell selection on immunological reconstitution. Leuk Lymphoma 2001 42 : 1207 1220.
78. Porrata LF, Litzow MR, Markovic SN. Immune reconstitution after autologous hematopoietic stem cell transplantation. Mayo Clin Proc 2001 76 : 407 412.
79. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004 39 : 797 802.
80. Safdar A. Strategies to enhance immune function in hematopoietic transplantation recipients who have fungal infection. Bone Marrow Transplant 2006 38 : 327 337.